Journal of Clinical Endocrinology & Metabolism, Vol 73, 837-842, Copyright © 1991 by Endocrine Society

ARTICLES

Dihydrospirorenone, a new progestogen with antimineralocorticoid activity: effects on ovulation, electrolyte excretion, and the renin- aldosterone system in normal women

W Oelkers, V Berger, A Bolik, V Bahr, B Hazard, S Beier, W Elger and A Heithecker
Department of Internal Medicine, Klinikum Steglitz, Freie Universitat Berlin, Germany.

Dihydrospirorenone (DHSP; 6 beta,7 beta,15 beta,16 beta-dimethylen-3- oxo-17- alpha-pregn-4-en-21,17-carbolacton) is an aldosterone antagonist 8 times as potent as spironolactone in the rat. It is also a progestogen that suppresses ovulation in normal women at a daily dosage of 2 mg. The effects of this dosage on the renin-aldosterone system and sodium and potassium balances were investigated in two experiments. In study I, 12 healthy women received a diet with 100 mmol sodium and 60- 70 mmol potassium per day from days 3-13 of their normal menstrual cycles. Six women took 2 mg DHSP; 6 others received placebo from days 8- 13 of the cycle. Sodium excretion in the DHSP group rose from a mean of 79 to 98.5 +/- 8.3 mmol/day during medication. Placebo had no effect. The difference between average sodium excretion rates in subjects treated with DHSP or placebo was close to significance (P = 0.053). Potassium excretion did not change. Weight loss was slightly greater after DHSP than placebo treatment. PRA and plasma and urinary aldosterone rose significantly during DHSP medication. In study II, 12 women on a free diet were studied during a control and a treatment cyle. From days 5-25 of the second cycle, they took 2 mg DHSP (n = 6) or 1 mg cyproterone acetate. Both compounds suppressed ovulation and the rise in progesterone. During cycle 1, sodium excretion, PRA, and aldosterone were higher in the luteal than in the follicular phase, probably due to an antialdosterone effect of progesterone. DHSP reversed this pattern of natriuresis by inducing a significant early natriuresis and a rise in PRA and aldosterone. Cyproterone acetate only abolished differences in natriuresis between the follicular and luteal phases and the rise of PRA and plasma aldosterone in the luteal phase. We conclude that DHSP may be a suitable partner of ethinyl estradiol as a constituent of an oral contraceptive, since its progestogenic and antialdosterone profile is similar to that of progesterone. Other synthetic progestogens are devoid of an antialdosterone effect. The antialdosterone effect of DHSP may help prevent sodium retention and a rise in blood pressure in susceptible women.

This article has been cited by other articles:

				D. Z. I. Cherney, J. W. Scholey, D. C. Cattran, A. K. Kang, J. Zimpelmann, C. Kennedy, V. Lai, K. D. Burns, and J. A. Miller The effect of oral contraceptives on the nitric oxide system and renal function Am J Physiol Renal Physiol, November 1, 2007; 293(5): F1539 - F1544. [Abstract] [Full Text] [PDF]

				E. D. Szmuilowicz, G. K. Adler, J. S. Williams, D. E. Green, T. M. Yao, P. N. Hopkins, and E. W. Seely Relationship between Aldosterone and Progesterone in the Human Menstrual Cycle J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 3981 - 3987. [Abstract] [Full Text] [PDF]

				R. Schurmann, H. Blode, N. Benda, M. Cronin, and A. Kufner Effect of drospirenone on serum potassium and drospirenone pharmacokinetics in women with normal or impaired renal function. J. Clin. Pharmacol., August 1, 2006; 46(8): 867 - 875. [Abstract] [Full Text] [PDF]

				D. A. Sica Drospirenone: An Antihypertensive in Waiting Hypertension, August 1, 2006; 48(2): 205 - 206. [Full Text] [PDF]

				R. Sitruk-Ware New progestagens for contraceptive use Hum. Reprod. Update, March 1, 2006; 12(2): 169 - 178. [Abstract] [Full Text] [PDF]

				M. Guido, D. Romualdi, M. Giuliani, R. Suriano, L. Selvaggi, R. Apa, and A. Lanzone Drospirenone for the Treatment of Hirsute Women with Polycystic Ovary Syndrome: A Clinical, Endocrinological, Metabolic Pilot Study J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 2817 - 2823. [Abstract] [Full Text] [PDF]

				D. l’Allemand, V. Tardy, A. Grüters, D. Schnabel, H. Krude, and Y. Morel How a Patient Homozygous for a 30-kb Deletion of the C4-CYP 21 Genomic Region Can Have a Nonclassic Form of 21-Hydroxylase Deficiency J. Clin. Endocrinol. Metab., December 1, 2000; 85(12): 4562 - 4567. [Abstract] [Full Text]